Novartis

Latest stories

3m
Business Wire
亚洲最大的业务洽谈盛会——来自30个国家的生物科技产业重要企业将齐聚BioJapan 2015!东京--(BUSINESS WIRE)--(美国商业资讯)--为期三天的BioJapan 2015将于10月14日(周三)至16日(周五)在横滨太平洋会展中心
亚洲最大的业务洽谈盛会——来自30个国家的生物科技产业重要企业将齐聚BioJapan 2015!
Business Wire / Posted 3 minutes ago
东京--(BUSINESS WIRE)--(美国商业资讯)--为期三天的BioJapan 2015将于10月14日(周三)至16日(周五)在横滨太平洋会展中心(Pacifico... Read more
3m
Business Wire
Asiens größtes Partnering-Event - Spitzenkräfte der Pharma und Biotechbranche aus 30 Ländern werden auf der BioJapan 2015 erwartet!TOKIO--(BUSINESS WIRE)--BioJapan 2015 wird an drei Tagen, vom 14. Oktober (Mitt
Asiens größtes Partnering-Event - Spitzenkräfte der Pharma und Biotechbranche aus 30 Ländern werden auf der BioJapan 2015 erwartet!
Business Wire / Posted 3 minutes ago
TOKIO--(BUSINESS WIRE)--BioJapan 2015 wird an drei Tagen, vom 14. Oktober (Mittwoch) bis zum 16. Oktober 2015 (Freitag) im Pacifico Yokohama stattfinden. BioJapan ist das größte Partnering-Event der Biotechnologie in Asien und bietet Messe, Seminare... Read more
3m
Business Wire
El Evento Comercial más Importante de Asia - ¡Las Empresas y Las Personas más Influyentes de la Industria de la Biotecnología de 30 Países se Reúnen en BioJapan 2015!TOKIO--(BUSINESS WIRE)--BioJapan 2015 se celebrará durante tres días desde el 1
El Evento Comercial más Importante de Asia - ¡Las Empresas y Las Personas más Influyentes de la Industria de la Biotecnología de 30 Países se Reúnen en BioJapan 2015!
Business Wire / Posted 3 minutes ago
TOKIO--(BUSINESS WIRE)--BioJapan 2015 se celebrará durante tres días desde el 14 (miércoles) hasta el 16 (viernes) de octubre de 2015 en Pacifico Yokohama. Con exhibiciones, seminarios y reuniones empresariales, BioJapan es el evento de asociación... Read more
3m
Business Wire
Plus grand événement de partenariats commerciaux en Asie - Des acteurs majeurs du secteur de la biotechnologie venus de 30 pays se réuniront lors du BioJapan 2015 !TOKYO--(BUSINESS WIRE)--BioJapan 2015 se déroulera pendant trois jours, du merc
Plus grand événement de partenariats commerciaux en Asie - Des acteurs majeurs du secteur de la biotechnologie venus de 30 pays se réuniront lors du BioJapan 2015 !
Business Wire / Posted 3 minutes ago
TOKYO--(BUSINESS WIRE)--BioJapan 2015 se déroulera pendant trois jours, du mercredi 14 au vendredi 16 octobre 2015, au Pacifico Yokohama. Avec ses salons, ses séminaires et ses réunions de partenariats, BioJapan est le plus grand événement de... Read more
3m
Business Wire
亞洲最大的業務洽談盛會——來自30個國家的生物科技產業重要企業將齊聚BioJapan 2015!東京--(BUSINESS WIRE)--(美國商業資訊)--為期三天的BioJapan 2015將於10月14日(週三)至16日(週五)在橫濱太平洋會展中心
亞洲最大的業務洽談盛會——來自30個國家的生物科技產業重要企業將齊聚BioJapan 2015!
Business Wire / Posted 3 minutes ago
東京--(BUSINESS WIRE)--(美國商業資訊)--為期三天的BioJapan 2015將於10月14日(週三)至16日(週五)在橫濱太平洋會展中心(Pacifico... Read more
3m
Business Wire
Maior evento de parceria de negócios da Ásia – Importantes organizações do setor de biotecnologia provenientes de 30 países se reúnem no BioJapan 2015!TÓQUIO--(BUSINESS WIRE)--O BioJapan 2015 será realizado durante três dias, de 1
Maior evento de parceria de negócios da Ásia – Importantes organizações do setor de biotecnologia provenientes de 30 países se reúnem no BioJapan 2015!
Business Wire / Posted 3 minutes ago
TÓQUIO--(BUSINESS WIRE)--O BioJapan 2015 será realizado durante três dias, de 14 (quarta-feira) a 16 (sexta-feira) de outubro de 2015, no Pacifico Yokohama. Com exposições, seminários e encontros de parceria, o BioJapan é o maior evento de parceria... Read more
3m
Business Wire
Asia's Largest Business Partnering Event - Biotech Industry Key Players from 30 Countries to Gather at BioJapan 2015!TOKYO--(BUSINESS WIRE)--BioJapan 2015 will be held for three days from October
Asia's Largest Business Partnering Event - Biotech Industry Key Players from 30 Countries to Gather at BioJapan 2015!
Business Wire / Posted 3 minutes ago
TOKYO--(BUSINESS WIRE)--BioJapan 2015 will be held for three days from October 14th (Wed) to 16th (Fri), 2015 at Pacifico Yokohama. Comprised of exhibitions, seminars, and partnering meetings, BioJapan is Asia's largest biotechnology partnering... Read more
32m
The Fremont Argus
FDA lays out proposal for naming lower-cost biotech drugsWASHINGTON -- The Food and Drug Administration released its proposal Thursday f
FDA lays out proposal for naming lower-cost biotech drugs
The Fremont Argus / Posted 32 minutes ago
WASHINGTON -- The Food and Drug Administration released its proposal Thursday for naming lower-cost biotech drugs, a critical step in creating a market for the new class of medicines. These quasi-generic biotech drugs have the potential to save the... Read more
54m
FOX News
FDA lays out proposal for naming lower-cost biotech drugsThe Food and Drug Administration has released its proposal for naming lower-cos
FDA lays out proposal for naming lower-cost biotech drugs
FOX News / Posted 54 minutes ago
The Food and Drug Administration has released its proposal for naming lower-cost biotech drugs, a critical step in creating a market for the new class of medicines. Biotech drugs are powerful, injected medicines produced in living cells which are... Read more
13 related stories
57m
KTEN North Texas & Southeastern Oklahoma
FDA lays out proposal for naming lower-cost biotech drugsWASHINGTON (AP) - The Food and Drug Administration released its proposal Thursd
FDA lays out proposal for naming lower-cost biotech drugs
KTEN North Texas & Southeastern Oklahoma / Posted 57 minutes ago
WASHINGTON (AP) - The Food and Drug Administration released its proposal Thursday for naming lower-cost biotech drugs, a critical step in creating a market for the new class of medicines. These quasi-generic biotech drugs have the potential to save... Read more
13 related stories
1h
Silicon Valley
FDA lays out naming rules for lower-cost biotech drugsWASHINGTON -- The Food and Drug Administration has released its proposal for na
FDA lays out naming rules for lower-cost biotech drugs
Silicon Valley / Posted an hour ago
WASHINGTON -- The Food and Drug Administration has released its proposal for naming lower-cost biotech drugs, a critical step in creating a market for the new class of medicines. Biotech drugs are powerful, injected medicines produced in living... Read more
13 related stories
1h
Hawaii News Now
FDA lays out proposal for naming lower-cost biotech drugsWASHINGTON (AP) - The Food and Drug Administration released its proposal Thursd
FDA lays out proposal for naming lower-cost biotech drugs
Hawaii News Now / Posted an hour ago
WASHINGTON (AP) - The Food and Drug Administration released its proposal Thursday for naming lower-cost biotech drugs, a critical step in creating a market for the new class of medicines. These quasi-generic biotech drugs have the potential to save... Read more
13 related stories
8h
Medical News Today
Contact lenses: a look at the risks and recommendationsThanks to the existence of contact lenses, it can sometimes be impossible to te
Contact lenses: a look at the risks and recommendations
Medical News Today / Posted 8 hours ago
Thanks to the existence of contact lenses, it can sometimes be impossible to tell if someone has a visual impairment or not. These lenses can make huge differences to the lives of their wearers, providing a certain level of freedom that traditional... Read more
18h
Business Wire
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale UniversityBOSTON--(BUSINESS WIRE)--Allied-Bristol Life Sciences, LLC, a biopharmaceutical
Allied-Bristol Life Sciences Licenses Platform Technology and Lead Molecules from Yale University
Business Wire / Posted 18 hours ago
BOSTON--(BUSINESS WIRE)--Allied-Bristol Life Sciences, LLC, a biopharmaceutical enterprise jointly owned between Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY), announced that it has entered into a worldwide licensing agreement... Read more
18h
Liverpool Echo
New future for Speke flu jab site after CSL Behring takeoverThe new owner of Speke’s flu vaccine plant, which employs almost 600 staff, ins
New future for Speke flu jab site after CSL Behring takeover
Liverpool Echo / Posted 18 hours ago
The new owner of Speke’s flu vaccine plant, which employs almost 600 staff, insists the Speke Boulevard site is core to its business. CSL Behring, based in King of Prussia, Pennsylvania in the US, announced an agreement to buy the plant from its... Read more
1d
PharmaceuticalOnline
Shaping The Emerging Biosimilars LandscapeBiosimilar drugs have been available in other countries for nearly a decade. In
Shaping The Emerging Biosimilars Landscape
PharmaceuticalOnline / Posted yesterday
Biosimilar drugs have been available in other countries for nearly a decade. In fact, more than 19 biosimilars are currently approved for use throughout Europe. However, the FDA only recently approved its first biosimilar for the U.S. market —... Read more
1d
News-Medical-Net
Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorderNovartis announced today that the US Food and Drug Administration (FDA) has app
Novartis receives FDA approval for expanded use of Promacta for younger children with rare blood disorder
News-Medical-Net / Posted yesterday
Novartis announced today that the US Food and Drug Administration (FDA) has approved an expanded use for Promacta® (eltrombopag) to include children 1 year of age and older with chronic immune thrombocytopenia (ITP) who have had an insufficient... Read more
1d
PharmaceuticalOnline
Brazil’s Pharmaceutical Market Value Will Approach 48B By 2020 Says GlobalDataBrazilian pharmaceutical market will expand in value from $29.4B in 2014 to app
Brazil’s Pharmaceutical Market Value Will Approach 48B By 2020 Says GlobalData
PharmaceuticalOnline / Posted yesterday
Brazilian pharmaceutical market will expand in value from $29.4B in 2014 to approximately $47.9B by 2020 ‘Brazil is now one of the most attractive and promising pharmaceutical markets in the world,’ says director The Brazilian pharmaceutical market... Read more
1d
Belfast Telegraph
Oxigen waste company fined 18,000 euro over Dublin recycling depot blaze Firefighters at the scene of the blaze in 2014 at the Oxigen plant in Ballymo
Oxigen waste company fined 18,000 euro over Dublin recycling depot blaze
Belfast Telegraph / Posted yesterday
Firefighters at the scene of the blaze in 2014 at the Oxigen plant in Ballymount, Dublin A leading waste company was fined 18,000 euro following a massive blaze at a recycling... Read more
2 related stories
2d
Japan Today
New tool will compare costs versus benefits of cancer treatments ‹ Japan TodayAs options for cancer patients become increasingly complicated, and expensive,
New tool will compare costs versus benefits of cancer treatments ‹ Japan Today
Japan Today / Posted 2 days ago
As options for cancer patients become increasingly complicated, and expensive, the most influential source for U.S. oncology treatment guidelines will for the first time offer a tool to assess the costs versus benefits of available therapies. The... Read more
2 related stories
2d
TheStreet.com
Specialty Pharma Firms That Could Be Potential Targets for Generics Giants Because of the consolidation among generics companies over the last several y
Specialty Pharma Firms That Could Be Potential Targets for Generics Giants
TheStreet.com / Posted 2 days ago
Because of the consolidation among generics companies over the last several years, the companies are running out of acquisition targets and as a result, specialty pharma... Read more
3d
The Scientist
Novartis Buys Rights to GSK MS Drug for $1 BillionWIKIMEDIA, OGUENTHERNovartis has purchased the full rights to GlaxoSmithKline (
Novartis Buys Rights to GSK MS Drug for $1 Billion
The Scientist / Posted 3 days ago
WIKIMEDIA, OGUENTHERNovartis has purchased the full rights to GlaxoSmithKline (GSK)’s ofatumumab, a monoclonal antibody therapy already approved for use in the U.S. to treat chronic lymphocytic leukemia, in a billion-dollar deal. The plan is to... Read more
3d
Business Wire
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune ThrombocytopeniaSAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
FDA Expands Use of Promacta® to Include Treatment of Children Ages 1 and Older with Chronic Immune Thrombocytopenia
Business Wire / Posted 3 days ago
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announces that the FDA has approved an expanded use for Promacta® (eltrombopag), a Novartis product, to include children 1 year of age and older with chronic immune... Read more
3d
Philly.com
New tool will compare costs versus benefits of cancer treatmentsOther medical groups are also trying to address the cost issue, but not as dire
New tool will compare costs versus benefits of cancer treatments
Philly.com / Posted 3 days ago
Other medical groups are also trying to address the cost issue, but not as directly as the NCCN. The American Society of Clinical Oncology (ASCO) is developing its own tool for valuing treatments, but says that its "net health benefit" scores will... Read more
2 related stories
3d
FOX News
New tool will compare costs and benefits of cancer treatmentsLOS ANGELES – As options for cancer patients become increasingly complicated, a
New tool will compare costs and benefits of cancer treatments
FOX News / Posted 3 days ago
LOS ANGELES – As options for cancer patients become increasingly complicated, and expensive, the most influential source for U.S. oncology treatment guidelines will for the first time offer a tool to assess the costs versus benefits of available... Read more
2 related stories
3d
The Courier Mail
CSL | The Australian BusinessNowCSL will begin the hunt for a new chief financial officer, after announcing inc
CSL | The Australian BusinessNow
The Courier Mail / Posted 3 days ago
CSL will begin the hunt for a new chief financial officer, after announcing incumbent Gordon Naylor has been tapped to lead the company’s new global influenza vaccine business. The new company is set to launch in early 2016 under the leadership of... Read more
4d
Japan Today
Alcon Japan leads eye care through innovation ‹ Japan TodayEyes are exposed to harsh environments due to modern lifestyle such as over-use
Alcon Japan leads eye care through innovation ‹ Japan Today
Japan Today / Posted 4 days ago
Eyes are exposed to harsh environments due to modern lifestyle such as over-use of PCs and smartphones in air-conditioned rooms. The number of Japanese dry eye patients is estimated at more than 20 million according to the Japanese Ophthalmological... Read more
94 related stories
5d
Zawya
New tool will compare costs and benefits of cancer treatmentsHealthcareLOS ANGELES, Aug 21 (Reuters) - As options for cancer patients become increasin
New tool will compare costs and benefits of cancer treatmentsHealthcare
Zawya / Posted 5 days ago
LOS ANGELES, Aug 21 (Reuters) - As options for cancer patients become increasingly complicated, and expensive, the most influential source for U.S. oncology treatment guidelines will for the first time offer a tool to assess the costs versus benefits... Read more
5d
Boston Herald
Novartis buying MS drug to stave off rivalSwiss drugmaker Novartis is buying a potential once-a-month multiple sclerosis
Novartis buying MS drug to stave off rival
Boston Herald / Posted 5 days ago
Swiss drugmaker Novartis is buying a potential once-a-month multiple sclerosis drug from GlaxoSmithKline for as much as $1 billion in its race against a competing medicine being developed by Roche Holding AG. Novartis, whose Institutes for... Read more
10 related stories
6d
Calcutta News
Novartis to buy potential MS drug from GSK in $1 bn deal BASEL - Swiss drug manufacturer Novartis has entered into a $1 billion deal t
Novartis to buy potential MS drug from GSK in $1 bn deal
Calcutta News / Posted 6 days ago
BASEL - Swiss drug manufacturer Novartis has entered into a $1 billion deal to acquire all remaining rights to multiple sclerosis drug Ofatumumab from GlaxoSmithKline plc (GSK) in a $1 billion... Read more
10 related stories
6d
Black Press USA
Glaxo Sells Rights to Auto-Immune Drug to Novartis This April 20, 2009 file photo shows signage at the offices of pharmaceutical
Glaxo Sells Rights to Auto-Immune Drug to Novartis
Black Press USA / Posted 6 days ago
This April 20, 2009 file photo shows signage at the offices of pharmaceuticals firm GlaxoSmithKline, in London. (AP Photo/Sang Tan, File) LONDON (MarketWatch) – GlaxoSmithKline PLC is selling its... Read more
10 related stories
6d
The Globe and Mail
Novartis to buy multiple sclerosis drug from GlaxoNovartis bolstered its portfolio of multiple sclerosis treatments on Friday by
Novartis to buy multiple sclerosis drug from Glaxo
The Globe and Mail / Posted 6 days ago
Novartis bolstered its portfolio of multiple sclerosis treatments on Friday by agreeing to buy an experimental drug from GlaxoSmithKline for up to $1-billion, the company said. Novartis, the Swiss pharmaceutical giant, acquired the rights this year... Read more
10 related stories
6d
The Register NorthJersey.com
Novartis buys rights to experimental MS drug for $1BGENEVA- Novartis agreed to buy the rights to an experimental multiple sclerosis
Novartis buys rights to experimental MS drug for $1B
The Register NorthJersey.com / Posted 6 days ago
GENEVA- Novartis agreed to buy the rights to an experimental multiple sclerosis drug from GlaxoSmithKline for as much as $1 billion as it races to catch up with a competing treatment being developed by Roche. Novartis will pay $300 million upfront... Read more
10 related stories
6d
TheStreet.com
How Google Wants to Help Change Diabetes Forever"These are massive markets that [Google and DexCom] are going after," said Raj
How Google Wants to Help Change Diabetes Forever
TheStreet.com / Posted 6 days ago
"These are massive markets that [Google and DexCom] are going after," said Raj Denhoy, equity analyst for Jefferies & Co. "It's intriguing when you look at the numbers in this arrangement, numbers in the $750 million to $5 billion for ultimate... Read more
6d
Philly.com
GSK gets $1 billion from Novartis for multiple sclerosis indication on cancer drugGlaxoSmithKline and Novartis said Friday they struck a deal under which Novarti
GSK gets $1 billion from Novartis for multiple sclerosis indication on cancer drug
Philly.com / Posted 6 days ago
GlaxoSmithKline and Novartis said Friday they struck a deal under which Novartis will pay GSK at least $300 million and perhaps more than $1 billion for the remaining rights to the drug ofatumumab. The drug is already approved for use in treating... Read more
10 related stories
6d
Business Insurance
New tool will compare costs and benefits of cancer treatments(Reuters) — As options for cancer patients become increasingly complicated and
New tool will compare costs and benefits of cancer treatments
Business Insurance / Posted 6 days ago
(Reuters) — As options for cancer patients become increasingly complicated and expensive, the most influential source for U.S. oncology treatment guidelines will for the first time offer a tool to assess the costs versus benefits of available... Read more
6d
heraldscotland
China woes send FTSE to its sharpest one-day fall in ten monthsThe top flight fell for a ninth day in a row, equalling a run of successive los
China woes send FTSE to its sharpest one-day fall in ten months
heraldscotland / Posted 6 days ago
The top flight fell for a ninth day in a row, equalling a run of successive losses seen in November 2011. The index is down 363 points this week, or 5.6 per cent, wiping £92.8 billion off the value of top-flight firms over the period. Germany's Dax... Read more
6d
The Irish Times
Novartis buys remaining rights to GSK treatment for up to $1 bln GlaxoSmithKline will be paid $300m for multiple sclerosis compound Ofatumumab
Novartis buys remaining rights to GSK treatment for up to $1 bln
The Irish Times / Posted 6 days ago
GlaxoSmithKline will be paid $300m for multiple sclerosis compound Ofatumumab upfront and $200m later Novartis had previously acquired the rights to Ofatumumab for oncology... Read more
10 related stories
6d
MedCity News
Novartis buys up rights to GSK's MS drug for up to $1B, anthrax vaccine developer Pfenex wins $143.5M contractNovartis has acquired the remaining rights to GlaxoSmithKline’s multiple sclero
Novartis buys up rights to GSK's MS drug for up to $1B, anthrax vaccine developer Pfenex wins $143.5M contract
MedCity News / Posted 6 days ago
Novartis has acquired the remaining rights to GlaxoSmithKline’s multiple sclerosis drug Ofatumumab for up to $1 billion. It is developing the drug for relapsing remitting multiple sclerosis and other auto-immune conditions. Pfenex Inc. a California... Read more
6d
Daily Telegraph
GSK sells cancer and multiple sclerosis drug to Novartis in $1bn dealThis latest deal effectivey gives Novartis the right to use Ofatumumab to treat
GSK sells cancer and multiple sclerosis drug to Novartis in $1bn deal
Daily Telegraph / Posted 6 days ago
This latest deal effectivey gives Novartis the right to use Ofatumumab to treat any medical conditions. Both transactions were part of a wider deal between GSK and Novartis, completed in March, in which the two companies have swapped billions of... Read more
10 related stories
6d
TheStreet.com
August 21 Premarket BriefingNEW YORK (TheStreet) -- Here are 10 things you should know for Friday, Aug. 21:
August 21 Premarket Briefing
TheStreet.com / Posted 6 days ago
NEW YORK (TheStreet) -- Here are 10 things you should know for Friday, Aug. 21: 1. -- U.S. stock futures were trading lower Friday after an ugly day in the market Thursday. Oil prices declined, Asian stocks dropped sharply and European stocks fell... Read more
6d
Investors Chronicle
Tritax Big Box, GlaxoSmithKline, Dragon Oil & more...News & Tips: Today's market overview Oil prices resumed their downward traje
Tritax Big Box, GlaxoSmithKline, Dragon Oil & more...
Investors Chronicle / Posted 6 days ago
News & Tips: Today's market overview Oil prices resumed their downward trajectory in Asian trade overnight following weak Chinese manufacturing data, as it's reported that non-Saudi OPEC... Read more
6d
Independent
The 10 things you need to know about business today2. Oil prices are down for the eight week running, pulled lower by weaker globa
The 10 things you need to know about business today
Independent / Posted 6 days ago
2. Oil prices are down for the eight week running, pulled lower by weaker global stock markets and a sharp contraction in China's manufacturing activity. US benchmark West Texas Intermediate (WTI) for October delivery, a new contract, lost 54 cents... Read more
6d
Evening Standard
China and Greece drag markets lowerIt could be a rocky day for traders as markets react to news of fresh elections
China and Greece drag markets lower
Evening Standard / Posted 6 days ago
It could be a rocky day for traders as markets react to news of fresh elections in Greece and poor data from China, but it might be a much more pleasant day for George Osborne if official data on Britain's public finances lives up to current... Read more
6d
Channel NewsAsia
Novartis buys remaining rights to GSK treatment in deal up to US$1 billionZURICH: Swiss drugmaker Novartis said on Friday it had agreed to buy all remain
Novartis buys remaining rights to GSK treatment in deal up to US$1 billion
Channel NewsAsia / Posted 6 days ago
ZURICH: Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is being developed for relapsing remitting multiple sclerosis and other autoimmune indications, from Britain's... Read more
10 related stories
6d
Channel NewsAsia
Novartis buys remaining rights to GSK treatment for up to US$1 billionZURICH: Novartis has agreed to buy all remaining rights to Ofatumumab from Brit
Novartis buys remaining rights to GSK treatment for up to US$1 billion
Channel NewsAsia / Posted 6 days ago
ZURICH: Novartis has agreed to buy all remaining rights to Ofatumumab from Britain's GlaxoSmithKline for up to US$1 billion, boosting the Swiss drugmaker's stable of multiple sclerosis (MS) treatments. Basel-based Novartis had previously acquired... Read more
10 related stories
6d
Reuters UK Edition
Novartis buys remaining rights to GSK treatment in deal up to $1 billionSwiss drugmaker Novartis' logo is seen behind scaffolding at the company's plan
Novartis buys remaining rights to GSK treatment in deal up to $1 billion
Reuters UK Edition / Posted 6 days ago
Swiss drugmaker Novartis' logo is seen behind scaffolding at the company's plant in the northern Swiss town of Stein January 27, 2015. ZURICH Swiss drugmaker Novartis said on Friday it had agreed to buy all remaining rights to Ofatumumab, which is... Read more
10 related stories
6d
Market Watch
GSK to sell ofatumumab rights to Novartis for $1BLONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it would sell its rights in of
GSK to sell ofatumumab rights to Novartis for $1B
Market Watch / Posted 6 days ago
LONDON--GlaxoSmithKline PLC (GSK.LN) said Friday it would sell its rights in ofatumumab for auto-immune indications, including multiple sclerosis, to Novartis AG NVS, -2.28% for up to $1 billion, plus royalties. The deal follows a previously agreed... Read more
6d
Swissinfo
Novartis to Acquire Rights to Glaxo MS Drug for Up to $1 Billion(Bloomberg) -- Novartis AG agreed to buy the rights to an experimental drug fro
Novartis to Acquire Rights to Glaxo MS Drug for Up to $1 Billion
Swissinfo / Posted 6 days ago
(Bloomberg) -- Novartis AG agreed to buy the rights to an experimental drug from GlaxoSmithKline Plc for as much as $1 billion, bolstering the Swiss company’s lineup of treatments for multiple sclerosis. Novartis will pay $300 million upfront to... Read more
6d
New Zealand's National Business Review
Why the R&D rules have changed and why it matters for companies and investorsTo build your own NBR Radio playlist and enjoy instant on-demand access to any
Why the R&D rules have changed and why it matters for companies and investors
New Zealand's National Business Review / Posted 6 days ago
To build your own NBR Radio playlist and enjoy instant on-demand access to any audio, sign up for our FREE smartphone-only subscription to NBR ONLINE. Henry Ford once famously said, "If I'd have asked my customers what they wanted, they would have... Read more
More

People in this news